3SBio Announces 2023 Interim Results: Over 20% Year-on-Year Growth, Continuous Improvement in Pipeline Value

PR Newswire ·  08/25/2023 09:45

Hong KongAugust 25, 2023/ PR Newswire /-- China's leading biopharmaceutical company Sansheng Pharmaceutical (01530.HK)August 24, 2023The interim results for 2023 were announced. In the first half of 2023, Sansheng Pharmaceutical achieved a total operating income of about 3.784 billion yuan, an increase of 22.3 percent over the same period last year; gross profit of about 3.202 billion yuan, an increase of 24.8 percent over the same period last year; normalized EBITDA of about 1.518 billion yuan, an increase of 17.7 percent over the same period last year; and normalized return net profit of about 1.191 billion yuan, an increase of 20.1 percent over the same period last year. In the future, Sansheng Pharmaceutical will maximize the advantages of an integrated platform for R & D, production, sales and foreign cooperation, and continue to create new performance growth points.

Core Biopharmaceuticals have strong vitality, and plate income has reached a new high.

In the first half of 2023, the revenue of Sansheng Pharmaceutical Biopharmaceutical sector increased steadily and continued to maintain a leading position in the market. The sales revenue of Terbiao, the only commercial recombinant human thrombopoietin (rhTPO) product in the world, was 2.019 billion yuan, an increase of 28.2% over the same period last year. This product was successfully renewed at the beginning of the year and was recommended as the highest level by the Chinese Society of Clinical Oncology (CSCO) guidelines for diagnosis and treatment of Thrombocytopenia caused by tumor treatment (CTIT) (2022 Edition).

Erythropoietin double brands Yibiao and Cyber maintain a leading position in the market, with sales revenue of 463 million yuan in the first half of 2023 and market share of 42.9%.

Yisaipu, which is used to treat rheumatoid arthritis, ankylosing spondylitis and psoriasis, had sales revenue of 300 million yuan in the first half of 2023, up 25.0% from the same period last year. Yisaipu pre-injection dosage form was approved and put on the market in March this year.

The sales revenue of Siptin, which is used to treat HER2-positive metastatic breast cancer, in the first half of 2023 was 109 million yuan, an increase of 60.5 percent over the same period last year. In the CSCO guidelines for the diagnosis and treatment of Breast Cancer (2022), Siptin is recommended as a first-line drug for advanced patients, significantly increasing the number of patients covered by Siptin in clinical practice.

Expand digital marketing, rapid growth of hair health products

Mandy, an OTC product for androgenic alopecia and alopecia areata, continues to maintain a rapid growth trend. The sales revenue of Mandy in the first half of 2023 was 496 million yuan, an increase of 35.3% over the same period last year. Minoxidil as a scientific, effective, safe and convenient means of hair generation, the degree of recognition is increasing, and the market scale is expanding year by year. As the leading brand of minoxidil, Mandy has a 70% market share in medical institutions, ranking first in the minoxidil market. In the first half of 2023, Mandy continued to promote patient education, expand digital marketing, cut into the new media operation platform and expand e-commerce marketing channels while deeply cooperating with the head platform. In the first half of the year, sales growth in the e-commerce field reached 64%, giving full play to the market potential of OTC products.

CDMO accelerates its growth

In the first half of 2023, Sansheng Pharmaceutical CDMO business grew further, with sector revenue of about 95 million yuan, an increase of 71.6% over the same period last year, overseas base revenue increased by 29% year-on-year, and domestic base revenue increased by 246%. At present, the total amount of orders signed by the group's CDMO business is about 160 million yuan, which shows good results by focusing on the differential positioning of commercial varieties of CDMO.

Clinical acceleration and continuous improvement of pipeline value

In the first half of 2023, the group had 30 products under research, including 10 in hematology / oncology, 13 in autoimmunity and ophthalmology, 5 in nephrology and 2 in skin and hair. Up to now, 10 new drugs have been advanced to the clinical III or NDA declaration stage, and 5 generic drugs are in the BE and ANDA declaration stage.

Research and development pipeline

In the first half of 2023, two important products of Sansheng Pharmaceutical were approved to be put on the market: Yisaipu pre-injection dosage form provides patients with more convenient treatment options and significantly improves the convenience of use. Nalorphine hydrochloride oral disintegrating tablet Limeizhi is the first drug on the market for pruritus in hemodialysis patients. At the same time, the application for phase III clinical trial of this product to improve pruritus in patients with chronic liver disease (only in cases where the existing treatment effect is not satisfactory) has been approved, which is expected to cover a larger population of patients.SSS06 is a long-acting recombinant human erythropoietin independently developed by the company. Phase II clinic shows that it ensures good safety while prolonging the administration interval to 2 weeks. At present, the final patients in phase III are out of the group, and it is expected that a research report will be obtained in the second half of the year to prepare for listing.

A number of auto-immunity product R & D tips based on the platform of subsidiary Sansheng Guojian reached a number of milestones in the first half of the year. At present, the three-phase clinical trial of anti-IL-17A antibody for the treatment of plaque psoriasis has been completed, and the II phase of anti-IL-1 β antibody for acute gouty arthritis and IL-4R α antibody for atopic dermatitis, chronic sinusitis with nasal polyps and moderate to severe chronic obstructive emphysema have reached the main end point. Anti-IL-5 antibodies for the treatment of asthma have completed phase II clinical trials of severe eosinophilic asthma. The commercialization of the company's innovative products has arrived, and it is expected that the heavyweight pipeline products will be promoted to the commercial stage every year in the future.

In addition, Winlevi, the company's cooperation with Cosmo, is actively promoting the bridging clinical application of Winlevi for acne indications. As the first new mechanism acne drug approved by FDA40 in the past year, Winlevi has been widely recognized by dermatologists in the United States. Since it was listed in December 2021, 15000 doctors have issued more than 670000 prescriptions, making it the largest prescription for acne in the United States. Driven by Sansheng Pharmaceutical, it is expected to become the first listed AR antagonist of Chinese mainland for the treatment of acne vulgaris, bringing new treatment options for hundreds of millions of acne patients in China.

Looking forward to the future research and development direction of Sansheng Pharmaceutical, on the one hand, the company will continue to focus on the advantageous areas such as nephrology, autoimmunity, blood, tumor and hair skin, on the other hand, it will focus on the whole world to promote the cooperative development of high-quality products. The company will adhere to independent research and development and foreign cooperation in parallel, and make every effort to promote drugs with real clinical needs and real value to be put on the market as soon as possible.

Dr. Lou Jing, Chairman and CEO of Sansheng Pharmaceutical, said: "in 2023, driven by the mission of" making innovative biopharmaceuticals within reach', Sansheng Pharmaceutical has entered its 30th year. At present, the company's business is booming, and its performance has maintained a good momentum of steady growth. Never forget why you started, and your mission can be accomplished. In the future, we will continue to focus on exploration and innovation in key areas, actively promote the development of the company's business lines, continue to implement corporate social responsibility, and promote more innovative biopharmaceutical products to the market for the benefit of patients. "

About Sansheng Pharmaceutical

Sansheng Pharmaceutical is a leading biopharmaceutical enterprise integrating R & D, production and sales, which is committed to improving the quality of life of patients with high-quality drugs for the benefit of human health. At present, the company has more than 100 national invention patents and more than 40 listed products, covering nephrology, oncology, autoimmune diseases, ophthalmology, dermatology and other treatment fields. The company has the National Engineering Research Center for Antibody drugs and four R & D centers on the dual platforms of biological drugs and chemical drugs, with a total of 30 products under development, 25 of which are national new drugs, and 5 major production bases that meet the GMP standards. In the future, Sansheng Pharmaceutical will continue to uphold the concept of "cherishing life, paying attention to survival and creating life", and make every effort to build the world's leading Sino Biopharmaceutical enterprise. Please visit for more information.

Warning statements and forward-looking statements

This press release contains forward-looking statements, such as those relating to business and product prospects, or the company's intentions, plans, perceptions, expectations and strategies. These forward-looking statements are based on the information available to the Company and are based on the forward-looking statements as at the time of this press release. These forward-looking statements are based on a number of projections, assumptions and premises, some of which are subjective or beyond our control. Such forward-looking statements may prove incorrect or may not be realized in the future. We cannot guarantee that any new product or new indication of a product will be successfully developed or eventually put on the market. These forward-looking statements are subject to various risks and uncertainties. Our other public disclosure documents may provide more information about these risks and uncertainties. The scientific information involved may be preliminary and research-oriented. Shareholders and potential investors of the Company should exercise caution when buying and selling shares in the Company.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment